



NEUROLOGICAL AUTOIMMUNITY WITH IMMUNE CHECKPOINT INHIBITORS



Roser Velasco, MD, PhD

Catalan Institute of Oncology- Bellvitge University Hospital
Associate Professor UAB

Barcelona, Spain

rvelascof@bellvitgehospital.cat

Conflict of interest



Speaker Takeda, Gilead-
Kite, Eisai, Janssen



Advisory board Novartis,
Seagen, Lab. Esteve



Research Grant Takeda

Learning objectives

Understand

- Understand the mechanisms of neurotoxicity due to Immune Checkpoint Inhibitors (ICI)

Recognize

- Recognize the clinical neurological syndromes associated with Immune Checkpoint Inhibitors (ICI)

Know

- Know the principles how to manage neurotoxicity due to ICI

Key messages

- ✓ Neurotoxicity due to ICI is a neuro-oncological emergency
- ✓ Can simultaneously affect several systems of the nervous system.
- ✓ Despite their low frequency (<5%), should be systematically considered in the patient treated with ICI
- ✓ May be reversible, require early recognition and detection
- ✓ Early therapeutic intervention is associated with better recovery
- ✓ Management of these complications is currently empirical and corticosteroid-based, with variable treatment response and prognosis
- ✓ Paraneoplastic syndromes associated with ICI are indistinguishable from spontaneous syndromes
- ✓ Retreatment with ICI may be considered in some patients
- ✓ Close communication and multidisciplinary care is essential

References

1. Wang DY, et al., Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 ;4(12):1721-1728.
2. Bruna J, Argyriou AA, Anastopoulou GG, et al. Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials. J Peripher Nerv Syst. 2020 Jun;25(2):171-177.
3. Marini A et al., Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review. Neurology 2021 Apr 20;96(16):754-766.
4. Fonseca E et al., Neurological adverse events related to immune checkpoint inhibitors in Spain: a retrospective cohort study. Lancet Neurology 2023 [in press]
5. Villagrán-García M, Velasco R. Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice. Neurol Sci. 2022 Apr;43(4):2339-2361.
6. Farina A, ..Velasco et al., The intersection of paraneoplastic neurological syndromes and neurotoxicity of immune checkpoint inhibitors. Lancet Neurology 2023 [In press]
7. Guidon AC et al., Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021 Jul;9(7):e002890.
8. Touat M et al., Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 2018 Sep 4;91(10):e985-e994.
9. Vilariño N, et al., Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors. Int J Mol Sci. 2020 11;21(16):5774.
10. Psimaras D, Velasco R, et al., Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment. Peripher Nerv Syst. 2019 Oct;24 Suppl 2:S74-S85.
11. Velasco R, et al., Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review. JAMA Neurol 2021 Jul 1;78(7):864-873.
12. Picca A, et al. Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors. Neurol Neuroimmunol Neuroinflamm. 2021 Feb 26;8(3):e967.
13. Vogrig A, et al. Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors. Neurology. 2021 Feb 9;96(6):e866-e875.
14. Dubey D et al., Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology . 2019 10;93(11):e1093-e1103.
15. Marco C et al., Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series J Clin Med 2022 Dec 24;12(1):130.
16. Brahmer JR, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021 Jun;9(6):e002435.
17. Haanen J, et al., Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Dec;33(12):1217-1238.
18. Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021; 39(36):4073-4126.
19. B Jordan et al., How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors ESMO Open. 2021 Dec;6(6):100317.
20. Dubey D et al., Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. Ann Neurol. 2020 May;87(5):659-669